28 Jan 2015 12:05
28 January 2015
Venn Life Sciences Holdings Plc
("Venn" or the "Company")
Grant of Share Options
& Total Voting Rights
Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation (CRO) providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces that it has today granted options over 2,870,000 ordinary shares representing to 10.12% of the current issued share capital.
Included in these options are options over 1,680,000 ordinary shares that have been granted to certain Directors (the "Director Options"), details of which are below:
Director | No. of ordinary shares under option | Percentage of issued share capital represented by the options | Exercise price | Exercise period |
|
|
|
|
|
Tony Richardson | 910,000 | 3.21% | 25p | From 28 January 2018 until 27 January 2025 |
Gracielle Beijerbacht-Schutjens | 770,000 | 2.72% | 25p | From 28 January 2018 until 27 January 2025 |
The Director Options vest when the share price reaches 40p per share.
The remaining options over 1,190,000 ordinary shares are being granted to a number of Venn Life Sciences employees. They are intended to reward commitment and loyalty, will be exercisable between the third and tenth anniversary of grant and have no performance criteria.
Following this grant the Company has granted options over 2,870,000 ordinary shares and has no intention to further increase the percentage of its issued share capital under option.
Total Voting Rights Correction
This announcement also corrects the figure for Total Voting Rights which was previously contained in an announcement on 8 September 2014. The Company's issued share capital consists of 28,359,221 ordinary shares. There are no ordinary shares held in treasury. Therefore, in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company confirms that the total number of voting rights in the Company are 28,359,221.
Venn Life Sciences Holdings Plc | www.vennlifesciences.com |
Tony Richardson, Chief Executive Officer | Tel: +353 154 99 341 |
Orla Mc Guinness, Marketing Manager | Tel: +353 153 73 269 |
|
|
Zeus Capital (Nominated Adviser and Broker) |
|
Ross Andrews/ Andrew Jones | Tel: +44 (0)161 831 1512 |
Dominic Wilson | Tel: +44 (0)20 7533 7727 |
|
|
Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or venn@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Lianne Cawthorne | Mob: +44 (0)7584 391 303 |
About Venn Life Sciences Limited:
Venn Life Sciences is a Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects. Venn recently established an innovation division - Innovenn - focused primarily on breakthrough development opportunities in Skin Science.